Aarti Pharmalabs (NSE:AARTIPHARM) Scaled Net Operating Assets: N/A (As of Mar. 2026)


NSE:AARTIPHARM Aarti Pharmalabs Ltd NSE:AARTIPHARM
55 GF Score
Price ₹680.05
GF Value ₹636.14
Valuation Fairly Valued
! 3 Warning Signs
View Full Analysis

What is Aarti Pharmalabs Scaled Net Operating Assets?

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Aarti Pharmalabs's operating assets for the quarter that ended in Mar. 2026 was ₹34,721 Mil. Aarti Pharmalabs's operating liabilities for the quarter that ended in Mar. 2026 was ₹6,027 Mil. Aarti Pharmalabs's Total Assets for the quarter that ended in Dec. 2025 was ₹0 Mil. Therefore, Aarti Pharmalabs's scaled net operating assets (SNOA) for the quarter that ended in Mar. 2026 was N/A.


Aarti Pharmalabs Scaled Net Operating Assets Historical Data

* Premium members only.

The historical data trend for Aarti Pharmalabs's Scaled Net Operating Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aarti Pharmalabs Scaled Net Operating Assets Chart

Aarti Pharmalabs Annual Data
Trend Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Scaled Net Operating Assets
Get a 7-Day Free Trial 6,578.42 0.84 0.87 0.91 0.99

Aarti Pharmalabs Quarterly Data
Mar21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Scaled Net Operating Assets Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

NSE:AARTIPHARM vs ZTS, UTHR: Scaled Net Operating Assets Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Aarti Pharmalabs's Scaled Net Operating Assets, along with its competitors' market caps and Scaled Net Operating Assets data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aarti Pharmalabs Scaled Net Operating Assets vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aarti Pharmalabs's Scaled Net Operating Assets distribution charts can be found below:

* The bar in red indicates where Aarti Pharmalabs's Scaled Net Operating Assets falls into.


NSE:AARTIPHARM
55GF Score
Aarti Pharmalabs Ltd NSE:AARTIPHARM
Scaled Net Operating Assets is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aarti Pharmalabs Scaled Net Operating Assets Calculation

Scaled Net Operating Assets (SNOA) is calculated as the difference between operating assets and operating liabilities, scaled by lagged total assets.

Aarti Pharmalabs's Scaled Net Operating Assets (SNOA) for the fiscal year that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(A: Mar. 2026 )
=(Operating Assets (A: Mar. 2026 )-Operating Liabilities (A: Mar. 2026 ))/Total Assets (A: Mar. 2025 )
=(34720.9-6027.399)/29064.051
=0.99

where

Operating Assets(A: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=34817.059 - 96.159
=34720.9

Operating Liabilities(A: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=13571.012 - 2379.874 - 5163.739
=6027.399

Aarti Pharmalabs's Scaled Net Operating Assets (SNOA) for the quarter that ended in Mar. 2026 is calculated as

Scaled Net Operating Assets (SNOA)(Q: Mar. 2026 )
=(Operating Assets (Q: Mar. 2026 )-Operating Liabilities (Q: Mar. 2026 ))/Total Assets (Q: Dec. 2025 )
=(34720.9-6027.399)/0
=N/A

where

Operating Assets(Q: Mar. 2026 )
=Total Assets - Cash, Cash Equivalents, Marketable Securities
=34817.059 - 96.159
=34720.9

Operating Liabilities(Q: Mar. 2026 )
=Total Liabilities - Long-Term Debt & Capital Lease Obligation - Short-Term Debt & Capital Lease Obligation
=13571.012 - 2379.874 - 5163.739
=6027.399

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Is Aarti Pharmalabs (NSE:AARTIPHARM) Overvalued in 2026?

Based on GuruFocus' analysis, Aarti Pharmalabs stock appears to be overvalued. The current stock price of ₹680.05 is trading 6.9% above its estimated GF Value™ of ₹636.14. GuruFocus considers Aarti Pharmalabs to be Fairly Valued.

Key valuation signals for NSE:AARTIPHARM:

  • Scaled Net Operating Assets: N/A
  • GF Value™: ₹636.14 vs. price of ₹680.05 (6.9% above fair value)
  • GF Score™: 55/100 with 3 warning signs

No single metric tells the full story. See the NSE:AARTIPHARM stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Aarti Pharmalabs Business Description

Other Exchanges 543748:India
Address Mulund Goregaon Link Road, 204, 2nd Floor, Udyog Kshetra, Mulund West, Mumbai, MH, IND, 400080
Aarti Pharmalabs Ltd manufactures pharmaceuticals and nutraceuticals with a footprint. The company manufactures Active Pharmaceutical Ingredients (API), pharmaceutical intermediates, acids, and xanthine derivatives, including caffeine, theophylline anhydrous, aminophylline, etophylline, and theophylline in India. It also offers Contract Development and Manufacturing Services (CDMS) for drug substance (NCE, RSM, Intermediates) projects. Geographically, the company generates maximum revenue from its customers located outside India.
55GF Score

Get the complete analysis for NSE:AARTIPHARM

Scaled Net Operating Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹680.05
Price
₹636.14
GF Value